secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
CIK:        0001757499
Form:       8-K
Filed at:   2025-01-21T23:59:59+00:00
Accession:  0001493152-25-002945
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shuttle Pharma reaches 25% enrollment in Phase 2 trial of Ropidoxuridine for glioblastoma
--------------------------------------------------------------------------------

- Initial randomization targets 40 patients: 20 at 1,200 mg/day, 20 at 960 mg/day to identify optimal dose.
- After optimal dose selected, 14 more patients will be enrolled for survival comparison vs. historical controls.
- Trial focuses on IDH wild-type, methylation-negative glioblastoma; standard care is radiation only.
- Ropidoxuridine previously received FDA Orphan Drug Designation; six major cancer centers are participating.
- CEO Anatoly Dritschilo said enrollment is ahead of expectations; no results or guidance changes reported.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1757499/000149315225002945/0001493152-25-002945-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1757499/000149315225002945/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-002945

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer